Form 4: Kiniksa COO Sells Shares After Option Exercise

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, executed pre-planned transactions, exercising stock options and subsequently selling a portion of the acquired shares.

Summary

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc (KNSA), engaged in transactions involving Class A Ordinary Shares.
• These transactions were conducted under a Rule 10b5-1 trading plan established on April 29, 2024.
• On September 4, 2025, Tessari exercised options to acquire 38,725 shares at $15.50 and 46,546 shares at $15.52.
• On the same day, 85,271 shares were sold at a weighted average price of $35.52, with individual trades ranging from $35.50 to $35.545.
• On September 5, 2025, Tessari exercised options to acquire an additional 13,389 shares at $15.52.
• Concurrently, 13,389 shares were sold at a weighted average price of $35.66, with individual trades ranging from $35.52 to $35.84.
• Following these transactions, Tessari's direct beneficial ownership of Class A Ordinary Shares is 44,452.
• All exercised options were fully vested and exercisable.

Sentiment

Score: 6

Explanation: The exercise of options indicates the stock price is above the strike price, which is positive. The subsequent sale, while reducing direct ownership, was pre-planned under a 10b5-1 plan, mitigating concerns about a negative signal. It's a routine event for executive compensation and liquidity.

Positives

• The Chief Operating Officer exercised stock options, indicating the options were in-the-money and had value.
• Shares were sold at significantly higher prices ($35.52 and $35.66) compared to the exercise prices ($15.50 and $15.52), demonstrating a substantial gain for the officer.
• Transactions were executed under a pre-arranged 10b5-1 plan, which suggests the sales were for personal financial planning (e.g., diversification, liquidity) rather than a reaction to new negative information about the company.

Negatives

• The Chief Operating Officer sold a significant number of shares (85,271 and 13,389 shares), which could be interpreted by some investors as a reduction in direct exposure to the company's future performance, even if pre-planned.
• The total number of shares beneficially owned by the officer decreased after these transactions.

Future Outlook

NA

Industry Context

This filing is specific to an individual's stock transactions and does not provide broader industry context. It is a routine disclosure for an executive in a publicly traded pharmaceutical company.

Stakeholder Impact

• Shareholders: May view the sale as a slight negative due to reduced insider ownership, but the 10b5-1 plan context generally mitigates this. The exercise of options at a profit could be seen as a positive signal of past performance.

Key Dates

Recommendation

The filing details routine insider transactions (option exercises and sales) executed under a pre-arranged 10b5-1 plan. These transactions are common for executive compensation and personal financial planning and do not typically signal a change in the company's fundamental outlook. While the sale reduces the officer's direct ownership, the pre-planned nature suggests it's not based on new, negative information. Therefore, the filing itself does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' is appropriate based solely on this specific disclosure. Investors should look to broader company fundamentals and market conditions for investment decisions.

Keywords

Kiniksa Pharmaceuticals, KNSA, SEC Form 4, Insider Trading, Stock Options, Share Sale, Eben Tessari, Chief Operating Officer, 10b5-1 Plan, Biotechnology, Pharmaceuticals